The open label study will assess the safety, tolerability and optimal dose of the antibody in up to 44 adult patients with malignant solid tumors and will even evaluate pharmacokinetics, changes in levels of markers that indicate anti-tumor activity.
Baxter BioScience business president Ludwig Hantson said, ”This research program leverages Baxter’s scientific expertise in systemic oncology therapies and leadership in biologics, and further reinforces our commitment of supporting patients with life-threatening conditions.”
The fully-human, recombinant anti-MIF monoclonal antibody has the potential to be a new therapeutic agent in treatment of cancer by targeting a specific antigen in the body.
The anti-MIF antibody targets the MIF protein and inhibits the cancer-promoting effects of MI thereby reducing the growth of tumors.